权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Children's Oncology Group Statistics and Data Center

儿童肿瘤学组统计和数据中心

基本信息

批准号：
10230673
负责人：
TODD A ALONZO
金额：
$ 83.01万
依托单位：
PUBLIC HEALTH INSTITUTE
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-04-15 至 2025-02-28
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10230673
关键词：
1 year old Acute Acute Myelocytic Leukemia Adolescent Advanced Development Australia Biology Brain Stem Glioma Canada Cancer Center Cancer Patient Cancer Survivor Caring Cause of Death Cell Therapy Child Child Support Childhood Childhood Cancer Treatment Childhood Leukemia Clinical Clinical Research Clinical Trials Clinical Trials Cooperative Group Clinical Trials Design Collaborations Collection Communities Companions Complication Country Data Diagnosis Disease Ensure Family Foundations Functional disorder Generations Genomics Goals Hormonal Immunotherapy Industry Infrastructure Institution Interdisciplinary Study Knowledge Laboratories Late Effects Malignant Childhood Neoplasm Malignant Neoplasms Methods Mission Molecular Morbidity - disease rate National Cancer Institute National Clinical Trials Network Neuroblastoma New Zealand Organ Outcome Patients Pediatric Hospitals Pediatric Oncology Group Pharmaceutical Preparations Population Heterogeneity Population Research Quality of life Rare Diseases Reporting Research Research Personnel Science Second Primary Cancers Survival Rate Survivors Time Tissues Translational Research United States Universities Work anticancer research base cancer therapy chemotherapy childhood cancer survivor data centers data management data sharing density design experience functional outcomes health related quality of life high risk improved improved outcome innovation member mortality multidisciplinary novel novel therapeutic intervention organizational structure outcome forecast programs reproductive small molecule statistics survivorship translational clinical trial translational scientist translational study trial design

项目摘要

PROJECT SUMMARY Since the introduction of chemotherapy for the treatment of childhood leukemia more than 60 years ago, the prognosis of childhood cancer has improved dramatically. The overall 5-year survival rate for childhood cancers, many of which were uniformly fatal in the pre-chemotherapy era, is now 84%. Progress for a number of childhood cancers, however, has been limited, with approximately 50% of children with acute myelogenous leukemia, 50% of children with high-risk neuroblastoma, and more than 90% of children with brainstem glioma, still succumbing to their disease. In the US, cancer remains the leading cause of death from disease in children greater than one year of age. Moreover, the late effects of cancer treatment, including permanent organ and tissue damage, hormonal and reproductive dysfunction and second cancers, are of special concern, with more than 40% of the estimated 360,000 survivors of childhood cancer experiencing a significant health related quality of life complication from childhood cancer and its treatment. Thus, despite our advances, development of new therapeutic approaches must be a priority for childhood cancer basic, translational and clinical researchers. The Children’s Oncology Group (COG), the world’s largest organization devoted exclusively to childhood and adolescent cancer research, was founded 17 years ago. The COG’s multidisciplinary research team, comprised of more than 9,000 members, conducts research at more than 220 leading children’s hospitals, universities, and cancer centers. This proposal is for COG, as part of the National Cancer Institute’s (NCI) National Clinical Trials Network (NCTN), to continue its collaborative research work that supports the mission of improving the outcome for all children with cancer. The COG will design and conduct clinical-translational studies for children with cancer that builds on an increasing understanding of the molecular basis for pediatric malignancies and has the highest potential to improve the outcome. Using innovative clinical trial designs suitable for the study of rare diseases, we will study novel therapeutic approaches including but not limited to targeted small molecule drugs, immunotherapies and cellular therapies. The COG research portfolio importantly also includes clinical trials focused on improving the quality of life children with cancer and survivors. As more than 90% of children diagnosed with cancer in the US are treated at COG member institutions, the COG has the ability to offer a diverse population of children with cancer and their families the opportunity to participate in innovative research. This research effort includes allowing for collection and annotation of biospecimens from all children with cancer, providing the foundation for discovery and accelerating the most promising research efforts conducted in laboratories around the world. The proposal is for support of the COG Network Statistics and Data Management Center which collaborates with COG scientific leaders to design, conduct, analyze and report the results of clinical-translational trials for the treatment of childhood cancers.

项目总结